Dicerna Pharma (DRNA) Misses Q3 EPS by 10c
Tweet
Share
E-mailGet Alerts DRNA Hot Sheet
Join SI Premium – FREE
Dicerna Pharma (NASDAQ: DRNA) reported Q3 EPS of ($0.35), $0.10 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $1.55 million versus the consensus estimate of $1.7 million.
For earnings history and earnings-related data on Dicerna Pharma (DRNA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
- ClearSign Technologies (CLIR) Tops Q2 EPS by 8c
- Beam Global (BEEM) Tops Q2 EPS by 8c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
